<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM17 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TRIM17</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TRIM17</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=TRIM17" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
TRIM17 (Tripartite Motif Containing 17), also known as RNF32, is a member of the tripartite motif (TRIM) family of E3 ubiquitin ligases. The TRIM family is characterized by a conserved architecture comprising a RING finger domain, one or two B-box domains, and a coiled-coil region, which together enable these proteins to function as E3 ligases that catalyze the transfer of ubiquitin to substrate proteins[@meroni2005]. TRIM17 is predominantly expressed in the brain, with high expression in the cerebellum, hippocampus, and cerebral cortex, regions critically involved in movement coordination and cognitive function that are prominently affected in various neurodegenerative disorders[@ncbi].
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM17 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TRIM17</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TRIM17</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=TRIM17" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
TRIM17 (Tripartite Motif Containing 17), also known as RNF32, is a member of the tripartite motif (TRIM) family of E3 ubiquitin ligases. The TRIM family is characterized by a conserved architecture comprising a RING finger domain, one or two B-box domains, and a coiled-coil region, which together enable these proteins to function as E3 ligases that catalyze the transfer of ubiquitin to substrate proteins[@meroni2005]. TRIM17 is predominantly expressed in the brain, with high expression in the cerebellum, hippocampus, and cerebral cortex, regions critically involved in movement coordination and cognitive function that are prominently affected in various neurodegenerative disorders[@ncbi].
The protein encoded by TRIM17 plays essential roles in regulating neuronal survival, [apoptosis](/entities/apoptosis), [mitophagy](/mechanisms/mitophagy), and protein quality control mechanisms within [neurons](/entities/neurons). TRIM17 has been implicated in the pathogenesis of several neurodegenerative diseases, including Huntington's disease (HD), spinocerebellar ataxia (SCA), Parkinson's disease (PD), and Alzheimer's disease (AD), through its interactions with disease-specific proteins and its regulation of key cellular pathways[@hatakeyama2017]. The gene is located on chromosome 1q42.13 and encodes a protein of approximately 462 amino acids with a molecular weight of approximately 52 kDa.
The TRIM17 gene spans approximately 7.5 kb of genomic DNA and consists of 3 exons. The protein structure follows the canonical TRIM family architecture: an N-terminal RING finger domain (C3HC4 type) that possesses E3 ubiquitin ligase activity, followed by two B-box domains (B-box 1 and B-box 2) that mediate protein-protein interactions, and a C-terminal coiled-coil region that facilitates homodimerization or heterodimerization with other TRIM proteins[@meroni2005]. The RING domain of TRIM17 contains the conserved cysteine and histidine residues required for zinc binding and catalytic activity, characteristic of RING-type E3 ligases.
Phylogenetic analysis places TRIM17 within the C-I subfamily of TRIM proteins, which also includes TRIM9, TRIM11, TRIM32, and TRIM67. These proteins share structural homology and have evolved specialized functions in neuronal systems. The brain-specific expression pattern of TRIM17 suggests specialized regulatory roles in neural development and maintenance, distinguishing it from more ubiquitously expressed TRIM family members.
TRIM17 functions as an E3 ubiquitin ligase, catalyzing the covalent attachment of ubiquitin to specific substrate proteins. The ubiquitination process involves three key enzymes: E1 (activating enzyme), E2 (conjugating enzyme), and E3 (ligase). TRIM17, through its RING domain, facilitates the transfer of ubiquitin from the E2 enzyme to the lysine residue on the substrate protein, marking it for degradation by the [26S proteasome](/proteins/26s-proteasome) or for non-degradative signaling functions[@chen2019].
The substrate specificity of TRIM17 is determined by its B-box domains and coiled-coil region, which mediate interactions with target proteins. TRIM17 has been shown to ubiquitinate several key neuronal proteins, including mutant huntingtin protein (mHTT), p53, and mitochondrial proteins, thereby regulating diverse cellular processes from apoptosis to mitochondrial quality control[@yan2019].
One of the most well-characterized functions of TRIM17 is its role in regulating [neuronal apoptosis](/entities/apoptosis). TRIM17 can both promote and inhibit apoptosis depending on context and interacting partners. TRIM17 interacts with anti-apoptotic proteins and can be recruited to the [mitochondria](/entities/mitochondria) to modulate the intrinsic apoptotic pathway[@yan2019].
In the context of neurodegeneration, TRIM17 has been shown to protect [neurons](/entities/neurons) from apoptotic cell death through several mechanisms. TRIM17 can ubiquitinate and regulate pro-apoptotic proteins, including Bim and Puma, targeting them for proteasomal degradation and thereby preventing their induction of mitochondrial outer membrane permeabilization (MOMP)[@liu2020]. Additionally, TRIM17 can interact with the tumor suppressor p53, modulating its transcriptional activity and stability, which influences the balance between survival and death in neuronal cells.
The regulation of apoptosis by TRIM17 is particularly relevant in polyglutamine diseases like Huntington's disease, where mutant huntingtin protein triggers aberrant apoptotic signaling. TRIM17 expression is modulated in HD models, and the protein has been shown to interact with mHTT, potentially influencing the survival of medium spiny neurons in the [striatum](/brain-regions/striatum)[@tourette2014].
TRIM17 plays a crucial role in [mitophagy](/mechanisms/mitophagy), the selective autophagy of damaged mitochondria, which is essential for maintaining mitochondrial homeostasis in [neurons](/entities/neurons). Mitochondrial dysfunction is a hallmark of many neurodegenerative diseases, and the proper regulation of mitophagy is critical for neuronal survival[@yang2020].
TRIM17 interacts with key mitophagy regulators, including Parkin and PINK1, which are mutated in familial Parkinson's disease. TRIM17 can be recruited to damaged mitochondria and contribute to the ubiquitination of mitochondrial outer membrane proteins, facilitating their recognition by autophagy receptors and subsequent engulfment by the autophagosome[@uribe2018]. In HD models, TRIM17 has been shown to regulate mitophagy pathways, potentially modulating the survival of neurons affected by mutant huntingtin-induced mitochondrial dysfunction[@wang2021].
The regulation of mitophagy by TRIM17 involves both ubiquitin-dependent and ubiquitin-independent mechanisms. TRIM17 can directly ubiquitinate mitochondrial proteins, creating recruitment signals for autophagosomal receptors like p62/SQSTM1 and optineurin. Additionally, TRIM17 can interact with ATG proteins to regulate the formation of the autophagosome around damaged mitochondria.
TRIM17 is involved in regulating the [endoplasmic reticulum](/entities/endoplasmic-reticulum) (ER) stress response and the unfolded protein response (UPR), which are critical for neuronal homeostasis under conditions of proteostatic stress. In neurodegenerative diseases, the accumulation of misfolded proteins triggers ER stress, leading to the activation of adaptive and pro-apoptotic UPR pathways[@yang2019].
TRIM17 can modulate ER stress signaling through its interactions with key UPR mediators. The protein has been shown to regulate the stability and activity of XBP1, a transcription factor critical for the adaptive UPR, and can influence the balance between pro-survival and pro-apoptotic signaling in the ER stress response. This function is particularly relevant in diseases characterized by protein aggregation, such as AD, PD, and HD.
Emerging evidence suggests that TRIM17 plays important roles in regulating synaptic function and neuronal activity. TRIM17 is localized to synaptic terminals and can regulate the ubiquitination of synaptic proteins, influencing synaptic plasticity, neurotransmitter release, and neuronal circuit function. The proper regulation of synaptic proteins through ubiquitination is essential for maintaining synaptic homeostasis, and dysregulation of this process contributes to synaptic dysfunction observed in neurodegenerative diseases.
TRIM17 has emerged as a significant player in Huntington's disease pathogenesis. The protein interacts with mutant huntingtin (mHTT) protein, the causative agent of HD, through its coiled-coil domain. This interaction influences the aggregation and toxicity of mHTT in [neurons](/entities/neurons)[@kim2016].
In HD models, TRIM17 expression is altered in the [striatum](/brain-regions/striatum) and [cortex](/brain-regions/cortex), brain regions particularly vulnerable in HD. TRIM17 can modulate the toxicity of mHTT through several mechanisms: by regulating the ubiquitination and degradation of mHTT aggregates, by influencing apoptotic pathways triggered by mutant protein, and by regulating mitochondrial function in affected neurons[@uribe2018].
The role of TRIM17 in mitophagy is particularly relevant to HD, as mitochondrial dysfunction is a central feature of the disease. TRIM17-mediated mitophagy pathways may help clear damaged mitochondria in neurons expressing mHTT, potentially delaying the progression of pathology. Therapeutic strategies targeting TRIM17 function could thus have beneficial effects in HD.
TRIM17 has been genetically linked to spinocerebellar ataxia (SCA), a group of autosomal dominant disorders characterized by progressive cerebellar degeneration and impaired motor coordination. Although the specific SCA subtype associated with TRIM17 remains under investigation, the gene's expression pattern in the cerebellum and its role in neuronal survival suggest potential involvement in cerebellar degeneration[@song2021].
The cerebellum expresses high levels of TRIM17, and the protein may regulate the survival of Purkinje cells and other cerebellar neuronal populations. Dysregulation of TRIM17 function could contribute to the selective vulnerability of cerebellar neurons in SCA, where protein aggregation and cellular stress are common pathogenic features.
While TRIM17 is not a major causal gene in familial PD, the protein's interactions with PD-related proteins and pathways suggest potential contributions to disease pathogenesis. TRIM17 can interact with Parkin and PINK1, the two most common causal genes in autosomal recessive PD, through its regulation of mitophagy[@yang2018].
Alterations in TRIM17 expression have been observed in PD models and patient tissue, suggesting that the protein may be involved in the neurodegenerative processes underlying PD. The regulation of mitochondrial quality control and apoptosis by TRIM17 could influence the survival of dopaminergic [neurons](/entities/neurons) in the [substantia nigra](/brain-regions/substantia-nigra), the brain region characteristically affected in PD.
TRIM17's involvement in Alzheimer's disease is an emerging area of research. TRIM17 can regulate the ubiquitination of amyloid precursor protein (APP) processing components and may influence the generation of [amyloid-beta](/proteins/amyloid-beta) peptides. Additionally, TRIM17's role in protein quality control and autophagy is relevant to AD, where the accumulation of misfolded proteins and dysfunctional organelles is a hallmark pathology.
TRIM17 expression is altered in AD brain tissue, and the protein may modulate tau pathology through interactions with tau kinases and phosphatases. The regulation of ER stress and the UPR by TRIM17 is also relevant to AD, as ER stress is prominently featured in AD pathogenesis[@iyer2022].
TRIM17 exhibits a brain-specific expression pattern with high levels in the [cerebellum](/brain-regions/cerebellum), [hippocampus](/brain-regions/hippocampus), [cerebral cortex](/brain-regions/cortex), and [striatum](/brain-regions/striatum). Within these regions, TRIM17 is expressed in both [neurons](/entities/neurons) and glial cells, although neuronal expression predominates.
At the subcellular level, TRIM17 localizes to the [cytoplasm](/entities/cytoplasm), with enrichment at the [mitochondria](/entities/mitochondria) and in proximity to the [endoplasmic reticulum](/entities/endoplasmic-reticulum). This localization pattern is consistent with its functions in regulating mitochondrial dynamics, ER stress, and apoptosis. TRIM17 can also be found at synaptic terminals, where it may regulate synaptic protein turnover.
TRIM17 represents a potential therapeutic target for neurodegenerative diseases due to its central roles in regulating neuronal survival, protein quality control, and mitochondrial function. Several therapeutic strategies could be envisioned:
Small Molecule Modulators: Compounds that enhance TRIM17 activity could promote neuronal survival and improve mitochondrial quality control in diseases like HD, PD, and AD. Conversely, inhibitors of TRIM17 might be beneficial in conditions where TRIM17 activity promotes pathology.
Gene Therapy: Viral vector-mediated delivery of TRIM17 or its modified variants could be used to modulate neuronal survival pathways. Adeno-associated viruses (AAV) targeting specific brain regions could achieve localized therapeutic effects.
Protein-Protein Interaction Inhibitors: Disrupting harmful interactions between TRIM17 and disease-specific proteins (e.g., mutant huntingtin) could reduce toxicity while preserving beneficial TRIM17 functions.
The development of TRIM17-targeted therapeutics requires careful consideration of the context-dependent nature of TRIM17 function, as both beneficial and detrimental effects have been documented in different disease contexts.
Several key questions remain regarding TRIM17 function and its therapeutic targeting: